Quarterly ResultAug 10, 2026, 08:47 AM
AIM ImmunoTech Reports Q2 2026 Results; Advances Ampligen to Phase 3
AI Summary
AIM ImmunoTech Inc. reported its financial results for the second quarter ended June 30, 2026, alongside significant operational advancements for its lead product, Ampligen. The company completed patient enrollment and Ampligen dosing in its Phase 2 DURIPANC study for metastatic pancreatic cancer and is preparing for a planned Phase 3 trial, with key data anticipated in Q1 and Q3 2027. Financially, AIM ImmunoTech reported a net loss of $3.8 million, or $0.43 per share, but strengthened its cash position to $9.9 million and regained compliance with NYSE American listing standards.
Key Highlights
- Completed patient enrollment and Ampligen dosing in Phase 2 DURIPANC study for metastatic pancreatic cancer.
- Anticipate DURIPANC clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027.
- Cash and cash equivalents totaled $9.9 million as of June 30, 2026, up from $3.0 million at Dec 31, 2025.
- Research and development expenses for Q2 2026 were $589,000, down from $1.2 million in Q2 2025.
- General and administrative expenses for Q2 2026 were $2.9 million, up from $1.5 million in Q2 2025.
- Net loss for Q2 2026 was $(3.8) million, or $(0.43) per share, compared to $(2.8) million in Q2 2025.
- Regained full compliance with NYSE American's continued listing standards.
Price Impact
More from AIM